Quinn Opportunity Partners LLC Immunovant, Inc. Transaction History
Quinn Opportunity Partners LLC
- $1.08 Billion
- Q2 2025
A detailed history of Quinn Opportunity Partners LLC transactions in Immunovant, Inc. stock. As of the latest transaction made, Quinn Opportunity Partners LLC holds 51,108 shares of IMVT stock, worth $1.41 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
51,108
Previous 35,100
45.61%
Holding current value
$1.41 Million
Previous $965,000
45.6%
% of portfolio
0.13%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding IMVT
# of Institutions
194Shares Held
78.9MCall Options Held
401KPut Options Held
354K-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.03MShares$193 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.88MShares$189 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.52% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$143 Million2.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...